NASDAQ:AMPH Amphastar Pharmaceuticals (AMPH) Stock Price, News & Analysis $27.72 +0.79 (+2.93%) Closing price 10/30/2026 04:00 PM EasternExtended Trading$27.73 +0.01 (+0.04%) As of 10/30/2026 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Amphastar Pharmaceuticals Stock (NASDAQ:AMPH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AMPH alerts:Sign Up Key Stats Today's Range$26.76▼$27.8050-Day Range$21.52▼$27.7252-Week Range$16.65▼$29.52Volume664,499 shsAverage Volume393,053 shsMarket Capitalization$1.18 billionP/E Ratio10.77Dividend YieldN/APrice Target$22.50Consensus RatingReduce Company Overview Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that develops, manufactures and markets injectable, inhalation and intranasal products. The company focuses on technically challenging medicines, including complex generics, proprietary products and products based on its drug-delivery technologies. Its product portfolio includes Primatene MIST, an over-the-counter epinephrine inhaler; Baqsimi, a nasal glucagon product used to treat severe hypoglycemia; and injectable medicines such as glucagon, naloxone, enoxaparin and hyaluronidase. Amphastar also maintains a pipeline of products in development across several therapeutic areas. Founded in 1996, Amphastar is headquartered in Rancho Cucamonga, California. The company markets its products primarily in the United States and also serves international markets. Amphastar is led by President and Chief Executive Officer Jack Zhang.AI Generated. May Contain Errors. Read More Amphastar Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreAMPH MarketRank™: 1.919369545395 of 5 starsAmphastar Pharmaceuticals scored higher than 38% of companies evaluated by MarketBeat, and ranked 709th out of 896 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.7 / 5Analyst RatingReduce Consensus RatingAmphastar Pharmaceuticals has received a consensus rating of Reduce. The company's average rating score is 1.88, and is based on no strong buy ratings, no buy ratings, 7 hold ratings, and 1 sell rating.Downside RiskAmphastar Pharmaceuticals has a consensus price target of $22.50, representing about 18.8% downside from its current price of $27.72.Amount of Analyst CoverageAmphastar Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Amphastar Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth4.94% Earnings GrowthEarnings for Amphastar Pharmaceuticals are expected to grow by 4.94% in the coming year, from $2.43 to $2.55 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amphastar Pharmaceuticals is 10.77, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.59.Price to Earnings Ratio vs. SectorThe P/E ratio of Amphastar Pharmaceuticals is 10.77, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 36.78.Price to Earnings Growth RatioAmphastar Pharmaceuticals has a PEG Ratio of 5.25. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAmphastar Pharmaceuticals has a P/B Ratio of 1.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Amphastar Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.47% of the float of Amphastar Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmphastar Pharmaceuticals has a short interest ratio ("days to cover") of 9.85.Change versus previous monthShort interest in Amphastar Pharmaceuticals has recently decreased by 1.62%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAmphastar Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmphastar Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.22 News SentimentAmphastar Pharmaceuticals has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Amphastar Pharmaceuticals this week, compared to 4 articles on an average week.MarketBeat Follows2 people have added Amphastar Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Amphastar Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $763,922.00 in company stock.Percentage Held by Insiders29.60% of the stock of Amphastar Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions65.09% of the stock of Amphastar Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Amphastar Pharmaceuticals' insider trading history. Receive AMPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amphastar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AMPH Stock News HeadlinesAmphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Stock Has Average Price Target of $22.50 According to AnalystsOctober 30 at 3:28 AM | americanbankingnews.comAmphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 5, 2026October 29 at 6:00 AM | prnewswire.comDon't lose access to thisIan Cooper's guide, 'The $50-to-$500 Options Strategy,' is still available for free download, but not for long. Tradewins plans to move the resource behind a paywall soon, closing off free access to the strategy breakdown. Readers who want a copy should grab it now, before the download link expires.October 31 at 1:00 AM | TradeWins (Ad)Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Rating Lowered by Wall Street ZenOctober 24, 2026 | americanbankingnews.comA look back at generic pharmaceuticals stocks’ Q2 earnings: Viatris (NASDAQ:VTRS) vs the rest of the packOctober 21, 2026 | msn.comAmphastar Pharmaceuticals (NASDAQ:AMPH) Stock Price Breaks Above 50-Day Moving Average - Here's WhyOctober 21, 2026 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and Madrigal Pharmaceuticals (MDGL)October 19, 2026 | theglobeandmail.comAmphastar Pharmaceuticals (AMPH) Stock Looks About Right After A 42% SlideOctober 17, 2026 | finance.yahoo.comSee More Headlines AMPH Stock Analysis - Frequently Asked Questions How have AMPH shares performed this year? Amphastar Pharmaceuticals' stock was trading at $26.78 at the beginning of the year. Since then, AMPH shares have increased by 3.5% and is now trading at $27.72. How were Amphastar Pharmaceuticals' earnings last quarter? Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) released its quarterly earnings data on Thursday, August, 6th. The company reported $0.91 earnings per share for the quarter, topping analysts' consensus estimates of $0.62 by $0.29. The company had revenue of $183.90 million for the quarter, compared to analyst estimates of $179.92 million. Amphastar Pharmaceuticals had a trailing twelve-month return on equity of 14.98% and a net margin of 10.76%. Read the conference call transcript. When did Amphastar Pharmaceuticals IPO? Amphastar Pharmaceuticals (AMPH) raised $88 million in an IPO on Wednesday, June 25th 2014. The company issued 8,000,000 shares at a price of $10.00-$12.00 per share. Who are Amphastar Pharmaceuticals' major shareholders? Top institutional investors of Amphastar Pharmaceuticals include Bridge City Capital LLC (0.90%), Robeco Institutional Asset Management B.V. (0.12%), Profund Advisors LLC (0.11%) and State of Alaska Department of Revenue (0.05%). Insiders that own company stock include Mary Z Luo, Rong Zhou, William J Peters, Yakob Liawatidewi, Floyd F Petersen, Richard K Prins and Michael A Zasloff. View institutional ownership trends. How do I buy shares of Amphastar Pharmaceuticals? Shares of AMPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Amphastar Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amphastar Pharmaceuticals investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Broadcom (AVGO), Salesforce (CRM), Eli Lilly and Company (LLY), Merck & Co., Inc. (MRK) and Super Micro Computer (SMCI). Company Calendar Last Earnings8/06/2026Today10/31/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 AMPH's financial health is in the Green zone, according to TradeSmith. AMPH has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:AMPH CIK1297184 Webwww.amphastar.com Phone(909) 980-9484Fax909-980-8296Employees1,976Year Founded1996Price Target and Rating Average Price Target for Amphastar Pharmaceuticals$22.50 High Price Target$30.00 Low Price Target$20.00 Potential Upside/Downside-18.8%Consensus RatingReduce Rating Score (0-4)1.88 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)$1.69 Trailing P/E Ratio10.77 Forward P/E Ratio11.41 P/E Growth5.25Net Income$98.09 million Net Margins10.76% Pretax Margin13.98% Return on Equity14.98% Return on Assets6.96% Debt Debt-to-Equity Ratio0.79 Current Ratio2.40 Quick Ratio1.71 Sales & Book Value Annual Sales$719.89 million Price / Sales1.64 Cash Flow$4.38 per share Price / Cash Flow6.33 Book Value$17.17 per share Price / Book1.61Miscellaneous Outstanding Shares42,540,000Free Float29,947,000Market Cap$1.18 billion OptionableOptionable Beta0.90 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:AMPH) was last updated on 10/30/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Withou...Behind the Markets | SponsoredLast note from me on thisJoel Peterson's free workshop breaks down a three step, three color system that works across stocks, ETFs, gol...The Cycle Code | SponsoredWhat Elon Musk's Cybercab Reveal Could Mean for InvestorsJeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredDon't lose access to thisIan Cooper's guide, 'The $50-to-$500 Options Strategy,' is still available for free download, but not for long...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amphastar Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amphastar Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
